A Phase 1/2, Open-Label, Multicenter, Dose Escalation and Expansion Study of KB707 in Subjects with Locally Advanced or Metastatic Solid Tumor Malignancies
Categories (click each to see list of all clinical trials associated with that category): Head & Neck (ONC), Melanoma (ONC), Sarcoma (ONC)
Current Status: Open
Phase: I (Cancer Control)
Principal Investigator: Sharma, Bhavina
Contact Information:
Michaela Savine
misavine@unmc.edu
Eligibility: https://clinicaltrials.gov/study/NCT05970497?term=KB707-01&rank=1#participation-criteria
Summary
Primary Objective
To evaluate the safety and tolerability of KB707 in adults with local or advanced metastatic solid tumor malignancies
Secondary Objectives
To evaluate whether the proposed dose ranges include the maximum tolerated dose of KB707
To evaluate preliminary efficacy of KB707
Exploratory Objectives Exploratory Endpoints
To assess the immunologic effect of KB707
To evaluate preliminary efficacy of KB707 beyond initial unconfirmed disease progression